1.23
+0.0855(+7.50%)
Currency In USD
Address
919 East Hillsdale Boulevard
Foster City, CA 94404
United States of America
Phone
650 473 7700
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
229
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Ms. Dawn Carter Bir | Interim President & Chief Executive Officer and Director | 64,158 | 1971 |
| Dr. Joseph Emile Eid M.D. | Executive Vice President of Research & Development | 304,098 | 1967 |
| Mr. Scott Samuels | Executive Vice President, Chief Legal Officer & Secretary | 485,317 | N/A |
| Mr. James Ziegler M.B.A. | Executive Vice President & Chief Commercial Officer | 618,670 | 1966 |
| Ms. Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer | 846,376 | 1967 |
| Dr. Andrew J. Grethlein Ph.D. | Executive Vice President & Chief Operating Officer | 977,476 | 1964 |
| Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Dr. Faye Feller M.D. | Executive Vice President & Chief Medical Officer | 0 | 1983 |
| Ms. Shannon T. Odam | Executive Vice President & Chief People Officer | 0 | 1975 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.